tbuckley/cabot-search huggingface dataset:
Triplet chemotherapy (TC) with FOLFIRINOX regimen in metastatic colorectal cancer (mCRC): Experience of two French centres.
Authors: Emmanuelle Samalin, Christelle De La Fouchardiere, Simon Thézenas, Matthieu Sarabi, Eric Assenat, Fabienne Portales, Sebastien Carrere, Michel Rivoire, Philippe Rouanet, Jean-Pierre Bleuse, François Quenet, Marc Ychou
Journal: Journal of Clinical Oncology (2015)

e14620 Background: TC is a treatment option for mCRC to improve the tumor response rate in selected patients (pts) and the conversion rate of initially non-resectable liver metastases. The aim of this study was to evaluate the impact and feasibility of FOLFIRINOX regimen in mCRC pts. Methods: We selected all mCRC pts from the ICM and CLB French centers with unresectable disease treated from October 2000 to December 2010 with FOLFIRINOX alone or combined with either bevacizumab or cetuximab. Clinical data were collected in a mCRC-specific data base and analysed. Results: 159 pts (52% of men), median age 58 yrs (range: 24-76) were treated with FOLFIRINOX (D1 oxaliplatin 85 mg/m² IV over 2H, then irinotecan 180 mg/m² IV over 90 min and elvorin 200 mg/m², then 5-fluorouracile 200 mg/m² and 2400 mg/m² IV over 46H, D1 = D15) alone (68%) or combined with cetuximab (24%) or bevacizumab (8 %) as first–line treatment (88%). Primary tumor was located in colon (77%) or rectum (23%), and 134 pts (84%) presented with synchronous metastases: liver (96%), lung (46%), peritoneum (11%) or nodes (20%). Median number of cycles was 8 (range: 1-26). There was 1 toxic death. Grade 3-4 toxicities were as follows: diarrhea (23%), neuropathy (24%), cutaneous (9%), neutropenia (21%), febrile neutropenia (1%), thrombopenia (4%). Objective response rate according to RECIST V1.0 was 72% [95%CI: 65-79] including 12 pts with complete response. The primary tumor was resected in 127 pts (79%) and 19% had a KRAS-mutated tumor. Among the 105 pts (66%) with initially non-resectable liver-limited disease (LLD), 59 pts (56%) were eligible for secondary resection and a R0 resection rate was achieved for 44 pts. Median overall survival was 49 months [95%CI: 37-62] and 72 months [95%CI: 48-84] in the resected-LLD population. Conclusions: Our results confirm the feasibility of FOLFIRINOX regimen with or without targeted therapies and its efficacy in LLD selected mCRC patients.
Autoimmune thrombocytopenic purpura (AITP) and acquired thrombasthenia due to autoantibodies to GP IIb–IIIa in a patient with an unusual platelet membrane glycoprotein composition
Authors: Laurent Macchi, Paquita Nurden, Gérald Marit, Claude Bihour, Gisèle Clofent‐Sanchez, Robert Combrié, Alan T. Nurden
Journal: American Journal of Hematology (1998)

The subject (E.B.) is a 63-year-old woman with autoimmune thrombocytopenic purpura (AITP) who was first examined some 6 years ago with symptoms of epistaxis and gum bleeding, severe thrombocytopenia, and large platelets. Her serum tested positively with control platelets in the MAIPA assay performed using monoclonal antibodies (MoAb) to glycoprotein (GP) IIIa (XIIF9, Y2/51), yet was negative in the presence of MoAbs to GP IIb (SZ 22) or to the GP IIb-IIIa complex (AP2, P2). The patient's platelets failed to aggregate with all agonists tested except for ristocetin. IgG isolated from the patient's serum inhibited ADP-induced aggregation of control platelets. Unexpectedly, flow cytometry showed an altered expression of membrane glycoproteins on the patient's platelets. Levels of GP Ib-IX were much higher than previously located by us in platelets. In contrast, the expression of GP IIb-IIIa was about half that seen with control subjects. When Western blotting was performed, a striking finding was a strong band of 250 kDa recognized by a series of MoAbs to GP Ibα in addition to the band in the normal position of GP Ibα. Finally, ADP-stimulated (E.B.) platelets failed to express activation-dependent epitopes on GP IIb-IIIa as recognized by PAC-1, AP6, or F26 and additionally gave a reduced P-selectin expression after thrombin addition. In conclusion, we present a novel patient with a severely perturbed platelet function where an altered membrane GP profile is associated with the presence of an autoantibody recognizing a complex-dependent determinant on GP IIb–IIIa and inhibitory of platelet aggregation. Am. J. Hematol. 57:164–175, 1998. © 1998 Wiley-Liss, Inc.
Error in Key Points
Authors: Joshua Geleris, George Shih, Lia Logio
Journal: JAMA Internal Medicine (2019)

All Patients Refined Diagnosis Related Groups (APR-DRG) weight is a measure of expected resource use that can serve as a proxy for illness severity for nonsurgical patients.It is generated from coded diagnoses at the end of a hospitalization.Because it is a measure of resource use, which may include laboratory tests, it is an imperfect measure, but it is the best we had available.We divided the total number of laboratory tests ordered by each resident by the average APR-DRG weight for all of their patients.We found that this adjustment did not change the variability in ordering habits.The ratio of total laboratory orders per unit APR-DRG weight for the top resident compared with the bottom resident was 7.2, which was similar to the unadjusted number.The linear regression equation for APR-DRG weight vs total laboratory tests ordered by each resident is 490.6 × (unit APR-DRG weight) + 4290 (R 2 = 0.007; P = .41).Additional studies should evaluate if there are better available measures of illness severity that might be more meaningfully applied to this data.We strongly agree that more research is needed to better understand the best means to promote high-value care.Ideally, future research would provide a more robust analysis of what influences practice habits, including controlled trials or studies that include a sustained change in provider ordering behavior. 2,3 We believe that understanding variability in practice patterns between individual physicians is the first step toward ensuring higher value care.
DENMARK
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
EDUCATIONAL NUMBER.
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BELGIUM
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Examining Product Risk in Context: The Case of Zomepirac-Reply
Authors: Thomas P. Gibson
Journal: JAMA (1994)

<h3>In Reply.</h3> —Dr Spielberg suggests that the company's "Dear Doctor" letter of April 9, 1982, describing reports of anaphylactic reactions to zomepirac was inadequate because it stated that those reactions were similar to those reported in association with the use of other nonsteroidal anti-inflammatory drugs. After the marketing of zomepirac in 1980, reports of adverse experiences resembling anaphylactic reactions were reported to Ortho-McNeil Pharmaceutical. A number of those reports occurred in aspirin-sensitive patients for whom zomepirac and other nonsteroidal anti-inflammatory drugs are contraindicated. These were promptly reported to the FDA. In close collaboration with the FDA, the company drafted and issued the Dear Doctor letter to draw attention to these reactions and provide additional information to physicians so that zomepirac could be properly prescribed. Advertising campaigns with appropriate fair balance have always been acceptable forms of promotion for approved and marketed medications. However, because of continued reports of anaphylactic reactions,
Family and Other Intimate Assaults—Atlanta, 1984
Journal: JAMA (1990)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Molecular Profiling of Diffuse Large B-Cell Lymphoma Identifies Robust Subtypes Including One Characterized by Host Inflammatory Response.
Authors: Stefano Monti, Kerry J. Savage, Jeffery L. Kutok, Friedrich Feuerhake, Paul Kurtin, Martin Mihm, Bingyan Wu, Laura Pasqualucci, Donna Neuberg, Ricardo C.T. Aguiar, Paola Dal Cin, Christine Ladd, Geraldine S. Pinkus, Gilles Salles, Nancy Lee Harris, Riccardo Dalla-Favera, Thomas M. Habermann, Jon C. Aster, Todd R. Golub, Margaret A. Shipp
Journal: Blood (2004)
PRACTICAL NOTES
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Acute Myeloid Leukemia (AML) Patients Understanding of Prognosis and Treatment Goals: A Mixed-Methods Study.
Authors: Thomas William LeBlanc, Catherine T Bloom, Debra M. Davis, Susan C. Locke, Karen E. Steinhauser, Peter A. Ubel, James A. Tulsky, Amy Pickar Abernethy
Journal: Journal of Clinical Oncology (2015)

e17741 Background: Patients with AML face complex information about the risks and rewards of pursuing treatments of varying intensity. Little is known about what patients understand or value in the decision-making process. Methods: AML inpatients receiving induction chemotherapy completed weekly electronic surveys about their prognosis and treatment goals, along with a baseline semi-structured, qualitative interview exploring their understanding of illness. Their oncologists (MDs) completed baseline surveys about prognosis and treatment goals. We followed a mixed-methods approach to analysis, applying standard statistical methods to survey data, and a constant-comparative qualitative approach to the interview data to enrich our understanding of survey results. Results: We enrolled thirteen dyads (a patient and MD pair). Mean patient age was 65.5, and all had high-risk disease due to either age > 60, complex cytogenetics, secondary AML, or relapsed disease. At baseline, mean MD-rated chance of cure was 27% (SD 17.6), while patients’ rating was 54% (SD 34.7; p = 0.02). Only 2 patients’ estimates of cure matched their MD’s rating, yet MDs rated their patients’ prognostic understanding as high (mean 7.2 on an 11-point scale). MDs reported an average of 3.1 available treatment options, but patients recalled just 1.5. Most MDs gave a specific treatment recommendation (11 of 13), and most patients received the recommended treatment (10 of 11). Agreement about treatment goal was markedly worse than expected by chance (kappa -0.41; 95% CI -0.88-0.07). Qualitative analysis suggests that patients often viewed treatment decisions as binary “life-or-death” propositions, rather than choices between options with differing goals and intensities. Patients also significantly underestimated the risks of induction chemotherapy. Conclusions: AML patients receiving induction chemotherapy have a poor understanding of their prognosis, treatment goals, and risks of induction chemotherapy, but their oncologists are not aware of this. These findings suggest the need for an intervention to improve patient understanding of their illness and treatment options.
CINCINNATI LETTER.
Authors: None Protoxide
Journal: JAMA (1883)

[ForThe Journal of the American Medical Association.] It has been the intention of your correspondent to have written ere this, and now fully agrees with Perseus, when he wrote: " Unhappy he who does his work adjourn, And to to-morrow would the search delay, His lazy morrow will be like to-day." From day to day has this pastime been adjourned only to find it much more easy to do so on the morrow. True, there has been little to write about. We are having a remarkably quiet summer and very little sickness. A cynic at my elbow claims that it is on account of so many of the profession being out of town; it remains to be seen whether that theory is any ways good when our new Board of Health is under full headway. Our Democratic council mortgaged itself by selecting a Board, composed of five saloon-keepers and an
Amer J of Clinical Nutrition, New York
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Peritoneal Transudate
Authors: Marlys H. Witte
Journal: JAMA (1972)

The protein content of ascitic fluid was determined in 26 patients with intra-abdominal neoplasms or inflammation in whom patency of the portal venous system was evaluated directly at laparotomy or autopsy. Ascitic fluid was high in protein content (respectively 54% and 62% of the plasma level) in both groups except when portal system occlusion was superimposed on the underlying disturbance, in which case ascitic fluid was low in protein content (respectively 8% and 24% of the plasma level). Viewed in the light of observations on the protein content of ascitic fluid in patients with hepatic cirrhosis, these data suggest that, in the absence of marked hypoproteinemia, peritoneal fluid of low protein content signifies marked impairment to portal blood flow into the liver.
Multiple Myeloma
Authors: Cynthia E. Dunbar
Journal: JAMA (1993)

<h3>SELECTED CASE</h3> A 57-year-old woman with multiple myeloma was referred to the National Heart, Lung, and Blood Institute for autologous bone marrow transplantation. She developed rib and back pain in October 1990. Her pain progressed and in May 1991 she was found to have a sedimentation rate of 131 mm/h, osteopenia, and anemia. She was referred to a hematologist, and workup revealed a total protein level of 101 g/L with a monoclonal IgA-λ of 52 g/L. Laboratory values were as follows: creatinine, 159.12 μmol/L (1.80 mg/dL); calcium, 2.74 mmol/L (11.00 mg/dL); and hemoglobin 99 g/L, with normal leukocyte and platelet counts; β<sub>2</sub>microglobulin was elevated, at 449175 nmol/L (5300 mg/L). Bone marrow aspiration and biopsy revealed 60% plasma cells, and roentgenograms revealed lytic lesions in the skull, humeri, and spine. The patient was treated with six cycles of monthly oral melphalan and prednisone. Her back pain resolved after two
MEDICAL ITEMS.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Questionable methods of cancer management: hydrogen peroxide and other 'hyperoxygenation' therapies
Journal: CA A Cancer Journal for Clinicians (1993)

"Hyperoxygenation" therapy--also called "oxymedicine," "bio-oxidative therapy," "oxidative therapy," and "oxidology"--is a method of cancer management based on the erroneous concept that cancer is caused by oxygen deficiency and can be cured by exposing cancer cells to more oxygen than they can tolerate. The most highly touted "hyperoxygenating" agents are hydrogen peroxide, germanium sesquioxide, and ozone. Although these compounds have been the subject of legitimate research, there is little or no evidence that they are effective for the treatment of any serious disease, and each has demonstrated potential for harm. Therefore, the American Cancer Society recommends that individuals with cancer not seek treatment from individuals promoting any form of hyperoxygenation therapy as an "alternative" to proven medical modalities.
Joint Sepsis: A Chance for Cure
Authors: Daniel J. McCarty
Journal: JAMA (1982)

Most types of joint inflammation can be controlled with empirical therapies, but only in septic joint inflammation is there an opportunity for cure. The retrospective analysis of 32 culture-proved cases of hematogenous septic arthritis in men by Ho and Su in this issue ofThe Journal(p 797) shows a strong direct correlation between duration of symptoms before treatment and the time needed to sterilize the joint fluid after treatment has begun. Time to sterilize the fluid correlated exceedingly well with treatment outcome, whereas the duration of symptoms did not. These findings are similar to those reported in a prospective study of septic bursitis by the same authors. It is generally accepted that the outcome of joint infection in a previously healthy person will be good if appropriate therapy is given within one week from the onset of symptoms. Delay in treatment beyond one week or the presence of serious